LSPL🇺🇸

LSPL, operating as Life Science Peptide Lab, receives one of the lowest KYP Vendor Scores in our entire database and a Grade D rating. This review contains serious and well-documented quality concerns that every researcher must read and understand before considering any purchase from this vendor. The evidence comes from multiple independent sources and is consistent enough to support an unambiguous editorial recommendation: do not use LSPL for any research application. The most critical data point for evaluating LSPL is the Finnrick independent quality testing program results for their Retatrutide product. Finnrick is an independent research quality testing organization that purchases vendor products anonymously at retail, without vendor knowledge, and subjects them to rigorous analytical testing including HPLC chromatography and biological activity assessment. The results are published without commercial bias. LSPL's Retatrutide received an E BAD rating on the Finnrick scale, with a minimum score of 1.6 out of 10 across tested samples. A minimum score of 1.6 out of 10 on the Finnrick scale does not mean the product is of low quality in the conventional sense. It means that at least one tested sample of LSPL Retatrutide was essentially biologically inactive or contained negligible amounts of the labeled compound. This is not a marginal quality shortcoming or a measurement error. This represents a product failure of categorical severity that should disqualify the vendor from serious research consideration. Multiple community researchers have confirmed the Finnrick findings through independent HPLC testing. Results documented in community reviews for LSPL Retatrutide have come back at seventy-nine to eighty-eight percent HPLC purity relative to labeled claims, consistent with the pattern of significant under-labeling suggested by the Finnrick data. Some researchers tested the product specifically because they saw the Finnrick E BAD rating and wanted to verify independently. Their results confirmed what the Finnrick data predicted. When the Finnrick testing program data is independently confirmed by multiple community researchers operating without coordination, the quality concern is established with a high degree of confidence that goes well beyond single-data-point uncertainty. The COA program at LSPL relies on in-house testing. This is the documentation standard that receives the lowest transparency score in our methodology, for a fundamental reason: in-house testing has no external accountability and gives the operator complete control over the reported results, creating obvious financial incentives to overstate purity figures. When a vendor with in-house testing produces products that fail independent verification at the level documented for LSPL Retatrutide, the in-house COA is revealed to be documentation that does not accurately represent the product quality. The LSPL situation is the clearest possible demonstration of why in-house COAs cannot substitute for independent external verification. The research implications of using LSPL products are serious and go beyond wasted money. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors, a compound where dosing accuracy is directly and critically tied to research outcomes. A researcher using LSPL Retatrutide that is largely or entirely inactive while believing they are working with the labeled compound is not merely wasting their budget. They are generating invalid research data. Every observation made, every control comparison conducted, and every research conclusion drawn from protocols using this compound becomes unreliable. The research validity damage extends to any publication or presentation derived from the affected work. Community reviews for LSPL are consistently negative. Reviewers describe poor product performance across compounds, quality concerns confirmed by independent testing, and unsatisfactory customer service responses when quality issues are raised. The pattern of customer service responses to quality concerns, specifically dismissiveness and deflection rather than investigation and remediation, is described consistently enough across reviews to be treated as a structural characteristic of how the vendor manages quality feedback. This is a significant additional concern beyond the product quality data itself. The LSPL quality profile extends the concern beyond Retatrutide specifically. When a vendor's COA program is in-house and one compound has been independently confirmed to be severely under-labeled or essentially inactive, there is no basis for confidence in the accuracy of COA claims across other compounds in their catalog. The lack of external verification means researchers have no credible third-party accountability for any LSPL compound. The appropriate response is to treat all LSPL products as unverified until independently tested, which effectively means treating them as unsuitable for research use without extensive verification infrastructure that most researchers do not have access to. There is no compound, no pricing consideration, and no availability argument that makes the LSPL quality risk profile acceptable for research use. When compounds are available from vendors with credible independent batch testing programs, including Kylo Peptides, Core Peptides, and Sports Technology Labs, sourcing from LSPL introduces quality uncertainty with no compensating benefit. Our recommendation: Do not purchase from LSPL for any research application. The Finnrick E BAD rating on Retatrutide, confirmed by multiple independent researcher HPLC tests, the in-house COA program with no external accountability, and the consistently negative community review data collectively establish a quality risk profile that is not acceptable for any serious research purpose. Redirect all sourcing to vendors with independent third-party batch testing programs. Grade D. Do not use.

-- KnowYourPeptide Research Team